Summary:
- The article presents data on the benefits of long-term administration of the dual-acting drug lecanemab for the treatment of Alzheimer's disease. Lecanemab is a monoclonal antibody that targets amyloid-beta, a key protein involved in the development of Alzheimer's.
- The data presented at the 17th Clinical Trials for Alzheimer's Disease (CTAD) conference showed that long-term treatment with lecanemab led to sustained reduction in amyloid levels and slowed cognitive decline in patients with early Alzheimer's disease.
- The findings suggest that lecanemab may be a promising therapeutic option for Alzheimer's disease, and the article highlights the ongoing clinical development of this drug by Eisai, a pharmaceutical company.